Search

Highlights of Past EHA (HOPE) Asia 2021

For the third edition of the Highlights of Past EHA (HOPE) Asia, EHA will organize a truly regional meeting by collaborating simultaneously with our hematology partners from the region.

Helping steer EHA into the future

May 12 2021

In 2020, EHA launched the Taskforce on Diversity, Equity, and Inclusion with an EHA Board mandate.

Abstract & travel grant submission

Abstract submission is closed

Abstract procedurePlease note that the submission of an abstract constitutes a formal commitment by the presenting author to present the abstract (if accepted) orally or as a poster in the session at the time assigned by the…

Sickle Cell Disease: From Research to Clinical Management

Elevate your expertise and impact patient care by joining the EHA's pilot preceptorship on Sickle Cell Disease, designed for early-career hematology specialists, clinicians, lab technicians, and pathologists.

COVID-19 Expert opinions

Expert opinions for hematologists in COVID-19 crisis
COVID-19, caused by SARS-CoV-2, is expected to be a devastating infection in many patients with hematologic diseases.

Abstract submission

Abstract submission is now closed. Abstracts guidelines:
– Your abstract has to be structured (eg Objectives, Methods, Results, Conclusions)
– Maximum number of words: 500
– Your abstract will be submitted to the peer review procedure.

Revision of the EU’s pharmaceutical legislation

Background on the reformIn April 2023, the European Commission (EC) published two proposals to revise the existing (and outdated) pharmaceutical legislation. This includes legislation on medicines for children and rare diseases.